BlueWind Medical
Evelops and markets an innovative wireless neuro-stimulation device for the treatment of peripheral neuropathic pain.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | $64.0m | Series B | |
| Total Funding | 000k | ||
Related Content
BlueWind Medical is a healthcare startup that offers a revolutionary treatment for Urge Urinary Incontinence (UUI), a condition characterized by urgent bladder leaks. The company's flagship product, Revi, is a miniature device implanted near the ankle. This device sends signals to the bladder via nerves, helping manage UUI symptoms.
The company primarily serves patients suffering from UUI, a widespread condition that can significantly impact quality of life. The market for such a solution is substantial, given the prevalence of UUI and the lack of effective long-term treatments.
BlueWind Medical operates on a business-to-consumer model, selling its product directly to patients through healthcare providers. The company generates revenue from the sale of the Revi device and potentially from follow-up services related to the device's adjustment and maintenance.
Revi has shown promising results in clinical studies, with 8 out of 10 participants experiencing a reduction in leaks after one year. The device is implanted in a single outpatient procedure under local anesthesia, making it a convenient and less invasive treatment option.
In summary, BlueWind Medical is a promising startup offering a novel, effective, and convenient solution for UUI, a condition that affects a significant portion of the population.
Keywords: BlueWind Medical, Urge Urinary Incontinence, Revi, bladder control, healthcare startup, outpatient procedure, patient satisfaction, clinical studies, convenient treatment, revenue generation.